Sermorelin

Sermorelin at a Glance

Sermorelin is GHRH(1-29), the shortest piece of growth-hormone-releasing hormone that still does the full job of the parent molecule. Because it works by prompting the pituitary to release its own growth hormone, output stays under normal feedback control rather than being imposed from outside — the reason this class is often preferred to injected growth hormone itself. It was approved by the FDA as Geref for diagnosing and treating growth-hormone deficiency in children, and withdrawn in 2008 for commercial rather than safety reasons. Today it is compounded and sold outside that approval, mostly for anti-ageing and body-composition use.

History & Development

Growth-hormone-releasing hormone was not found by looking for it in a healthy brain. It was isolated from a pancreatic tumour that was causing acromegaly - the tumour was making so much of the hormone that it could finally be purified.

First described	GHRH isolated and characterised in 1982; sermorelin is its 1-29 fragment 19Reference 19Guillemin et al. · 1982Growth hormone-releasing factor from a human pancreatic tumor that caused acromegalyView study →
Discovered / synthesised by	Roger Guillemin and colleagues (44-amino-acid form); Rivier, Spiess, Thorner and Vale (40-amino-acid form), independently 19Reference 19Guillemin et al. · 1982Growth hormone-releasing factor from a human pancreatic tumor that caused acromegalyView study →
Institution	The Salk Institute for Biological Studies 19Reference 19Guillemin et al. · 1982Growth hormone-releasing factor from a human pancreatic tumor that caused acromegalyView study →
Origin	Synthetic fragment - the first 29 amino acids of human GHRH
Key patent	Not established in the sources consulted for this section
Assignee	n/a
Development status	Formerly approved - FDA, GEREF, 28 December 1990 and 26 September 1997; discontinued 2008 for commercial reasons 20Reference 20U.S et al. · 2013Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectivenessView study →

Discovery

For decades GHRH was a hypothesised molecule. Growth hormone clearly came from the pituitary under hypothalamic control, but the releasing factor itself resisted isolation because it exists in vanishingly small quantities in normal tissue.

The breakthrough came from pathology. In 1982 two groups independently characterised the hormone from pancreatic islet cell tumours that were producing it ectopically in large amounts and causing acromegaly in the patients carrying them. Guillemin’s group at the Salk Institute reported a 44-amino-acid peptide; Rivier, Spiess, Thorner and Vale characterised a 40-amino-acid form ^{19Reference 19Guillemin et al. · 1982Growth hormone-releasing factor from a human pancreatic tumor that caused acromegalyView study →}. Guillemin had already received the Nobel Prize in 1977 for earlier work on hypothalamic hormones.

Sermorelin is the 1-29 fragment of that molecule - established as the shortest piece retaining receptor binding and GH-releasing activity comparable to the full-length peptide. Everything after the 29th residue turned out to be dispensable.

Development & ownership

Sermorelin was approved by the FDA as GEREF, first on 28 December 1990 and again on 26 September 1997 for a second presentation, indicated for diagnosing and treating growth-hormone deficiency in children.

Its disappearance is the part usually misreported. GEREF was voluntarily discontinued in 2008 for commercial reasons, and the FDA subsequently issued a formal determination in the Federal Register that it was “not withdrawn from sale for reasons of safety or effectiveness” ^{20Reference 20U.S et al. · 2013Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectivenessView study →}. That distinction is legally meaningful - it is the finding that permits abbreviated applications referencing the withdrawn product - and it is why sermorelin can still be compounded lawfully.

How it reached the market

Sermorelin today reaches patients almost entirely through compounding pharmacies operating under 503A and 503B provisions, rather than as an FDA-approved finished drug product - no approved sermorelin product is currently marketed in the United States. It is prescribed largely for anti-ageing and body-composition purposes, which is neither the indication it was approved for nor a use supported by the trials that secured that approval.

What It's Used For

Sermorelin is GHRH(1-29)NH2 — the first 29 amino acids of human growth-hormone-releasing hormone, the shortest N-terminal fragment that keeps full biological activity. It binds the pituitary GHRH receptor and makes the pituitary release its own growth hormone in pulses, with hypothalamic feedback intact, rather than replacing GH from outside. Its place on this hub is unusual, and it is the thing to understand first: sermorelin was an FDA-approved drug. It held two US new drug applications as Geref and Geref Diagnostic (EMD Serono) — approved in December 1990 and September 1997 for GH-stimulation testing and for treating idiopathic growth-hormone deficiency in children — and EMD Serono voluntarily discontinued both in 2008, with FDA formally withdrawing the approvals in June 2009 (Drugs@FDA; 74 FR, 19 May 2009). In 2013 FDA published a determination that Geref “[was] not withdrawn for reasons of safety or effectiveness” (78 FR, 4 March 2013). So it is neither a never-approved research chemical nor a currently approved medicine — it is a withdrawn drug, and the compounding pharmacies and anti-aging clinics that now sell it trade heavily on that former approval.

That history is exactly where the honesty problem lies. The approved indications were pediatric GH deficiency and diagnostic testing — and the genuine human evidence, small and dating from the 1980s–90s, sits there and nowhere else. Not one controlled trial has ever tested sermorelin for the adult uses it is now compounded and marketed for — anti-aging, body recomposition, fat loss, sleep, injury recovery, libido. What gets cited for those is trial data on other GHRH analogues, principally tesamorelin, which is the stabilized member of this family and the one that is still FDA-approved (for HIV-associated lipodystrophy). Route is load-bearing throughout: sermorelin is injected subcutaneously because it has negligible oral bioavailability, and the parent peptide is gone within minutes.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

Adult anti-aging, fat loss, muscle gain, injury healing and libido — the uses sermorelin is actually sold for — are deliberately absent from this table. They rest on vendor and clinic marketing, not on evidence, and are not scored.

01Diagnosis of GH deficiencyPromising70%Human; a former FDA-approved diagnostic indication; provocative-test data. Cannot exclude hypothalamic-origin GHD; product discontinued.

02Pediatric GH-deficiency treatmentPromising62%Human; a former FDA-approved indication. Small, largely open-label 1980s–90s trials; never displaced rhGH.

03Body composition and metabolic agingShaky32%Human RCTs — but of GHRH analogues ([Nle27]GHRH, tesamorelin), not sermorelin. Modest effects.

04Cognition in older adultsShaky26%One positive human RCT — tesamorelin, not sermorelin — that two later trials failed to confirm.

05Slow-wave sleepShaky24%Human neuroendocrine work on GHRH generally, not sermorelin-specific; no sleep-outcome trial.

06Cardiac repair after myocardial infarctionShaky18%Animal only (swine, rat), and using potent synthetic agonists (MR-409), not sermorelin.

07Recurrent gliomaShaky12%In-silico transcriptomic drug screen only. No cell, animal or human validation.

Mechanisms

Pharmacokinetics

Sermorelin is given by subcutaneous injection (intravenously for the diagnostic test); oral bioavailability is negligible, as for peptides of this size, so any oral “sermorelin” product cannot deliver intact peptide regardless of what the label claims. Human PK was characterized directly in 30 healthy men: intravenous GHRH(1-29)NH2 was rapidly eliminated, yet the GH response it triggered kept GH elevated for about 3 hours — the same peptide-versus-effect mismatch seen with tesamorelin, and the reason bedtime dosing works ^{4Reference 4Wilton P et al. · 1993Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration — human (PK / dose-response, n=30)View study →}. That study also tested an intranasal route and found absorption through the nasal mucosa poor, with bioavailability of only 3–5%; roughly 50 µg/kg intranasally was needed to match 1 µg/kg intravenously ^{4Reference 4Wilton P et al. · 1993Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration — human (PK / dose-response, n=30)View study →}. A precise human elimination half-life is not established in the accessible literature — figures in the 10–20-minute range circulate but trace to class knowledge rather than a specific measured value in the sources reviewed here.

The short duration is the load-bearing PK fact. It is why continuous-infusion and depot formulations were explored in the approved era to make sustained therapy practical ^{1,5Reference 1Prakash A · 1999ReviewSermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — reviewView study →Reference 5Brain CE et al. · 1990Clinical trialContinuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children — human (clinical trial, n=8 children)View study →}, and it is why findings generated with stabilized analogues — tesamorelin, [Nle27]GHRH, MR-409 — cannot be assumed to transfer to native sermorelin, whose exposure profile is entirely different. Sermorelin is supplied as a lyophilized powder requiring reconstitution, with refrigeration and limited stability once mixed; specific stability parameters for compounded and gray-market product are not independently documented.

Clinical & regulatory status

Sermorelin acetate held two US new drug applications, both now withdrawn. Per Drugs@FDA: NDA 19-863 (Geref Diagnostic, 0.05 mg base/ampoule) was approved 28 December 1990 as a new molecular entity, and NDA 20-443 (Geref, 0.5 and 1.0 mg base/vial) was approved 26 September 1997; both were held by EMD Serono and both are listed as Discontinued. EMD Serono notified FDA in July and December 2008 that the products were being discontinued and requested withdrawal of approval on the grounds that they were no longer marketed; the withdrawals took effect 18 June 2009 (74 FR, 19 May 2009). FDA subsequently published a determination that Geref “[was] not withdrawn for reasons of safety or effectiveness” (78 FR, 4 March 2013) — a finding made specifically so that abbreviated new drug applications referencing it could be approved. No primary source states the manufacturer’s actual business rationale; “withdrawn for commercial reasons” is a fair inference from a voluntary, non-safety withdrawal, but it is an inference, and it will not be dress it up as a documented fact.

There is consequently no approved sermorelin product in the US today. It circulates through two channels: compounding pharmacies, dispensing it on prescription for individual patients (an FDA-tolerated compounding pathway, not an approval, and one whose status FDA has been actively reviewing across the peptide category), and unregulated “research chemical” vendors selling powder outside the prescription system entirely. It is a prescription agent, not a dietary supplement, and is not a scheduled or controlled substance.

Registered-trial activity that is genuinely sermorelin is essentially nil. A ClinicalTrials.gov search returns 42 records matching the term, but they are dominated by tesamorelin and generic GHRH studies — including NCT02931474 (GHRH for sleep after traumatic brain injury), which used tesamorelin and was withdrawn. The active GHRH pipeline belongs to tesamorelin, not to sermorelin. Counts below reflect what is findable and verifiable in PubMed and ClinicalTrials.gov this pass.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status — the distinguishing fact. Sermorelin is a withdrawn drug, which puts it in a category of its own on this hub: not a never-approved research chemical like most peptides here, and not a currently approved medicine like tesamorelin. It was FDA-approved as Geref Diagnostic (1990) and Geref (1997), EMD Serono voluntarily discontinued both in 2008, and the approvals were withdrawn in June 2009; FDA determined in 2013 that this was not for reasons of safety or effectiveness. Anyone reading that as an endorsement should stop at the limits: the approval covered GH-stimulation testing and pediatric growth-hormone deficiency, and it ended seventeen years ago. It never covered adult use, and there is no approved sermorelin product to point to now. The clinics and compounders selling it for anti-aging are borrowing credibility from a lapsed pediatric approval — that is the single most important thing to understand about how this compound is marketed.

How it’s supplied and administered. Sermorelin ships as a lyophilized (freeze-dried) powder that must be reconstituted — typically with bacteriostatic water — before use, and is given by subcutaneous injection, conventionally at bedtime to align with the natural nocturnal GH pulse. The diagnostic use was intravenous, as a single dose. Oral routes do not work: a 29-amino-acid peptide is digested rather than absorbed, so oral products are pharmacologically inert. The intranasal route was investigated and found poor — 3–5% bioavailability ^{4Reference 4Wilton P et al. · 1993Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration — human (PK / dose-response, n=30)View study →} — so nasal formulations require enormous dose multiples to do anything. Reconstituted solution needs refrigeration and has limited shelf life; the dry powder keeps longer if kept cold and dry.

Sourcing reality (this is a safety issue, not a footnote). Two channels, two different risk profiles. Compounded prescription sermorelin from a licensed pharmacy is the more controlled of the two, but compounded preparations are not FDA-approved products — they are not reviewed for safety, efficacy or manufacturing quality the way an approved drug is, and FDA has been actively scrutinizing the bulk-substance pathway that peptide compounding depends on, so availability is not stable. Gray-market “research use only” powder has no oversight at all: uncertain identity and actual peptide content, mislabeling, under- or over-concentration, bacterial endotoxin, and no sterility guarantee. Reconstitution and self-injection add technique and contamination risk on top. A vendor’s own certificate of analysis is not independent verification and can be falsified. None of the human efficacy data here were generated with either compounded or gray-market material — they came from a manufactured pharmaceutical that no longer exists. This page does not recommend or link vendors.

Safety

Sermorelin has real adverse-event data from an approved-era clinical program, and it was generally well tolerated — but that record belongs to children with GH deficiency dosed for up to a year under supervision, not to healthy adults dosing indefinitely with compounded material. Read the tolerability as evidence about a different use.

Safety at a Glance

❔ Toxicity unknownDrug interactions

• Active or suspected malignancy is the clearest reason to avoid it. GHRH agonism and IGF-1 elevation are theoretically pro-proliferative, and GHRH receptors appear on some tumor tissue.
• Contraindicated in pregnancy and breastfeeding by default. No reproductive data exist — see the box below.
• No long-term adult safety data at all. The approved-era data cover about a year of dosing in children; the modern adult use has never been tested.
• GH-excess effects follow the mechanism. Fluid retention, arthralgia and myalgia, carpal-tunnel symptoms, and impaired glucose tolerance.
• Interactions not formally assessed. Stacking with other GH secretagogues compounds IGF-1 elevation and is entirely unstudied.
• Injection-site reactions were the commonest problem in trials. Redness, pain and swelling, with flushing, headache or dizziness less often.

Full Safety & Interactions Detail

Overall posture. Sermorelin has something almost nothing else on this hub has: real adverse-event data from an approved-era clinical program. In the pediatric GHD and diagnostic trials it was generally well tolerated — the largest study reported no adverse changes in biochemical or hormonal analyses, no change in fasting glucose, and no excessive IGF-1 generation over a year of daily dosing in children ^{2Reference 2Thorner M et al. · 1996Clinical trialOnce daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy (Geref International Study Group) — human (multicentre open-label clinical trial, n=110 children)View study →}. Commonly reported effects across the GHRH(1-29) literature are injection-site reactions (redness, pain, swelling) and, less often, flushing, headache, dizziness or transient nausea. Anti-GHRH antibodies developed in 14 of 18 children on chronic therapy in one series, with no apparent effect on growth or on GH responsiveness ^{3Reference 3Ross RJ et al. · 1987Clinical trialTreatment of growth-hormone deficiency with growth-hormone-releasing hormone [GHRH(1-29)NH2] — human (clinical trial, n=18 children)View study →} — a genuine immunogenicity finding whose long-term significance was never established, because the drug left the market.

The limits of that reassurance. That safety record belongs to children with GH deficiency, dosed for up to a year, under medical supervision, with a manufactured pharmaceutical product. It does not transfer to healthy adults dosing indefinitely for cosmetic reasons with compounded or gray-market material — a population, a duration, an indication and a supply chain that have never been studied. Read the pediatric tolerability as what it is: evidence about a different use.

Mechanistic risks that follow the GH axis. Sermorelin raises GH and therefore IGF-1. Sustained elevation carries the GH-excess concerns familiar from recombinant GH — fluid retention, arthralgia and myalgia, carpal-tunnel-type symptoms, and impaired glucose tolerance or insulin resistance. These are expected to be less pronounced than with exogenous GH, because GHRH stimulation preserves pituitary feedback and pulsatility rather than overriding them, but “less pronounced” is a mechanistic argument, not a measured outcome in adults. Contemporary clinical reviews of unregulated GH-IGF-1-axis peptides report exactly this cluster in self-administering users — dysglycemia, fluid retention, myalgia and arthralgia, injection-site reactions, and prolactin or cortisol disturbance — alongside biologically plausible but unproven mitogenic concerns ^{17,18Reference 17Dominikowski A et al. · 2026ReviewThe emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — reviewView study →Reference 18Mendias CL · 2026ReviewSafety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance — reviewView study →}.

The proliferation question. Because GHRH agonism and IGF-1 elevation are theoretically pro-proliferative, and because GHRH receptors are expressed on some tumor tissue ^{15Reference 15Schally AV et al. · 2019ReviewActions and potential therapeutic applications of growth hormone-releasing hormone agonists — reviewView study →}, active or suspected malignancy is the clearest reason to avoid it. This is the same concern that appears as a formal contraindication on the tesamorelin label, and it is the strongest argument against unsupervized use: for the one approved drug in this class, IGF-1 monitoring is part of the prescription.

Interactions. Not formally assessed for adult use. On mechanistic grounds only: GH response may be blunted by agents that suppress GH secretion (somatostatin analogues, glucocorticoids) and is influenced by thyroid status; stacking with other GH-axis stimulants — ipamorelin, GHRP-2, GHRP-6, CJC-1295, MK-677 — compounds the IGF-1 elevation and is the norm in community protocols. That is mechanism-based reasoning about a common practice, not data from a controlled interaction study.

Who should avoid it. Anyone with active or suspected malignancy; anyone pregnant, breastfeeding or trying to conceive; children outside a diagnosed and supervised GHD indication; anyone with diabetes or impaired glucose tolerance without supervision; and anyone unwilling to accept a non-approved product of unverified composition. Injection-specific risks — non-sterile technique, contaminated product, endotoxin — scale with how far the supply sits from a licensed pharmacy.

Scope disclosure (honesty, not a claim):

• Human data? Yes, but narrow and old — human clinical data exist for GH-stimulation testing and pediatric GHD treatment (the former FDA-approved indications, 1980s–90s, mostly small and open-label). No human efficacy data exist for any adult use. Adult body-composition, cognition and sleep data come from other GHRH analogues, not sermorelin.
• Interactions assessed? No. The notes above are mechanism-based; no controlled interaction study in adults exists, and stacking with other GH secretagogues is entirely unstudied.
• Pregnancy/lactation assessed? No — not established; avoid.
• Long-term safety established? No. The approved-era data cover roughly a year of dosing in children. There is no long-term adult safety data at all, and the immunogenicity finding ^{3Reference 3Ross RJ et al. · 1987Clinical trialTreatment of growth-hormone deficiency with growth-hormone-releasing hormone [GHRH(1-29)NH2] — human (clinical trial, n=18 children)View study →} was never followed up.
• Does the former approval make it safe for current use? No — and this is the specific misreading to guard against. The approval covered one population and two indications, ended in 2009, and says nothing about indefinite adult use with non-approved product.

Never imply safety from silence. Where sermorelin has not been studied — adult efficacy, long-term dosing, interactions, pregnancy, compounded and gray-market product quality — the correct statement is “not assessed,” not “safe.”

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not assessed / not established. No adequate human pregnancy or lactation data exist for sermorelin, and no reproductive-toxicity data were located. Treat as contraindicated by default in pregnancy and breastfeeding.

Dosage

There is no established adult dose for sermorelin, and none is recommended here. No controlled trial has ever dose-ranged it in adults for any purpose. Every figure below is an approved-era clinical dose reported as historical data, not a protocol and not a recommendation — and none of it was generated for the uses sermorelin is now sold for.

The diagnostic dose was a single ~1 µg/kg intravenously, which is near the top of the dose-response curve; 0.25 µg/kg IV already produced significant GH release and 1–2 µg/kg gave maximal release in healthy men ^{1,4Reference 1Prakash A · 1999ReviewSermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — reviewView study →Reference 4Wilton P et al. · 1993Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration — human (PK / dose-response, n=30)View study →}. The pediatric therapeutic dose was 30 µg/kg subcutaneously once daily at bedtime in prepubertal children with GH deficiency ^{2Reference 2Thorner M et al. · 1996Clinical trialOnce daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy (Geref International Study Group) — human (multicentre open-label clinical trial, n=110 children)View study →}; earlier protocols used twice-daily subcutaneous injection ^{3Reference 3Ross RJ et al. · 1987Clinical trialTreatment of growth-hormone deficiency with growth-hormone-releasing hormone [GHRH(1-29)NH2] — human (clinical trial, n=18 children)View study →} or continuous subcutaneous infusion at 60 ng/kg/min ^{5Reference 5Brain CE et al. · 1990Clinical trialContinuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children — human (clinical trial, n=8 children)View study →}. If an intranasal route is being considered, note that bioavailability is only 3–5% and roughly 50 µg/kg intranasally was required to match 1 µg/kg intravenously ^{4Reference 4Wilton P et al. · 1993Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration — human (PK / dose-response, n=30)View study →} — the large multiple is the measurement, not a suggestion.

The doses used in adult anti-aging compounding are not here, because there is nothing to source them from except vendor copy and clinic protocols, and this site does not launder those into dose figures. Growth benefit in the pediatric trials was also maintenance-dependent — height velocity reverted to pretreatment rates in every child once treatment stopped ^{5Reference 5Brain CE et al. · 1990Clinical trialContinuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children — human (clinical trial, n=8 children)View study →} — so the trial results describe continuous dosing, not a course with a lasting result. Oral products cannot deliver intact peptide (see Pharmacokinetics), whatever the label says.

References

1. Prakash A, Goa KL. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — review. BioDrugs. https://pubmed.ncbi.nlm.nih.gov/18031173/
2. Thorner M, et al. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy (Geref International Study Group) — human (multicentre open-label clinical trial, n=110 children). Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/8772599/
3. Ross RJ, et al. (1987). Treatment of growth-hormone deficiency with growth-hormone-releasing hormone [GHRH(1-29)NH2] — human (clinical trial, n=18 children). Lancet. https://pubmed.ncbi.nlm.nih.gov/2879138/
4. Wilton P, et al. (1993). Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration — human (PK / dose-response, n=30). Acta Paediatrica Supplement. https://pubmed.ncbi.nlm.nih.gov/8329825/
5. Brain CE, et al. (1990). Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children — human (clinical trial, n=8 children). Clinical Endocrinology (Oxford). https://pubmed.ncbi.nlm.nih.gov/2140733/
6. Khorram O, et al. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women — human (RCT, GHRH analogue). Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/9141536/
7. Makimura H, et al. (2014). The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced growth hormone — human (RCT, tesamorelin). Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/24178787/
8. Baker LD, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults — human (RCT, tesamorelin). Archives of Neurology. https://pubmed.ncbi.nlm.nih.gov/22869065/
9. Aimaretti G, et al. (2004). GHRH and GH secretagogues: clinical perspectives and safety — review. Pediatric Endocrinology Reviews. https://pubmed.ncbi.nlm.nih.gov/16456487/
10. Merriam GR, et al. (1997). Potential applications of GH secretagogues in the evaluation and treatment of the age-related decline in growth hormone secretion — review. Endocrine. https://pubmed.ncbi.nlm.nih.gov/9449031/
11. Ellis RJ, et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity — human (phase 2 RCT, tesamorelin). Journal of Infectious Diseases. https://pubmed.ncbi.nlm.nih.gov/39813152/
12. Stewart CE, et al. (2026). The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition rated normal to mildly impaired — human (placebo-controlled pilot trial). eNeurologicalSci. https://pubmed.ncbi.nlm.nih.gov/42382101/
13. Steiger A. (1998). Effects of hormones on sleep [GHRH and slow-wave sleep] — review (human neuroendocrine). Hormone Research. https://pubmed.ncbi.nlm.nih.gov/9550112/
14. Bagno LL, et al. (2015). Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy — animal (swine, MR-409). Journal of the American Heart Association. https://pubmed.ncbi.nlm.nih.gov/25827134/
15. Schally AV, et al. (2019). Actions and potential therapeutic applications of growth hormone-releasing hormone agonists — review. Endocrinology. https://pubmed.ncbi.nlm.nih.gov/31070727/
16. Chang Y, et al. (2021). A potentially effective drug for patients with recurrent glioma: sermorelin — in silico (transcriptomic drug screen, n=1,018 patients). Annals of Translational Medicine. https://pubmed.ncbi.nlm.nih.gov/33842627/
17. Dominikowski A, et al. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — review. Frontiers in Endocrinology. https://pubmed.ncbi.nlm.nih.gov/42395176/
18. Mendias CL, Awan TM. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance — review. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/
19. Guillemin, R., Brazeau, P., Bohlen, P., Esch, F., Ling, N., & Wehrenberg, W. B. (1982). Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science, 218(4572), 585-587. https://pubmed.ncbi.nlm.nih.gov/6812220/
20. U.S. Food and Drug Administration (2013). Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams

View all 20 references▾